Interferon Lambda Therapy for COVID-19

SARS-CoV-2 Clinical Trial

Official title:

A Randomized Phase 2 Trial of Peginterferon Lambda-1a (Lambda) for the Treatment of Hospitalized Patients Infected With SARS-CoV-2 With Non-critical Illness

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT04388709
• Other study ID #: GCO 20-0820
• Status: Withdrawn
• Phase: Phase 2
• Start date: September 2020
• Est. completion date: February 5, 2021

Study information

• Verified date: February 2021
• Source: Icahn School of Medicine at Mount Sinai
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The main purpose of this research study is to test the safety and effectiveness of an investigational drug peginterferon lambda-1a in treating COVID-19.

Description:

Primary Objective: Determine efficacy of pegylated interferon lambda as measured by clinical improvement. This will be defined as improvement in supplemental oxygen requirement. Secondary Objectives: - Determine safety and tolerability of pegylated interferon lambda - Days with fever - Time to resolution of fever - Rate of progression to requiring critical care - Overall survival - Time to discharge Exploratory Objectives: Determining the effect systemically on inflammatory markers in the blood, as well as viral load. Diagnosis and Main Inclusion Criteria: Patients must have a confirmed diagnosis of infection with SARS-CoV-2 and be receiving supplemental oxygen. Many patients may be receiving hydroxychloroquine with or without other antimicrobials.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: February 5, 2021
• Est. primary completion date: February 5, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Confirmed diagnosis of SARS-CoV-2
• Hospitalization due to diagnosis with SARS-CoV-2
• Sp02 < 93% on ambient air or PaO2/FiO2 < 300 mmHg and requires supplemental oxygen

Exclusion Criteria:

• Patients must not be pregnant or nursing
• Patients cannot be admitted to intensive care unit at time of admission or require positive pressure ventilation
• Patients cannot be requiring continuous supplemental oxygen normally (pre-SARS-CoV-2)
• Patient is receiving steroids >1mg/kg
• Has diagnosis of primary immunodeficiency
• Has active autoimmune disease that has required systemic treatment in the past year
• Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial
• Patients with ferritin >2000ng/mL and/or C-reactive protein >100mg/L
• History of allogeneic hematopoietic cell transplantation or solid organ transplantation
• Childs-Pugh class B or C cirrhosis or class A if portal hypertension is present
• Documented allergic or hypersensitivity response to protein therapeutics
• No serious disease requiring mechanical ventilation at time of enrollment

Related Conditions & MeSH terms

• SARS-CoV-2

Intervention

Drug:
• Peginterferon Lambda-1A
Peginterferon lambda-1a (Lambda) 180mcg subcutaneous injection once

Locations

Country	Name	City	State
n/a

Sponsors (2)

Lead Sponsor	Collaborator
Icahn School of Medicine at Mount Sinai	Eiger BioPharmaceuticals

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of participants with resolution of hypoxia	The clinical improvement as defined as resolution of hypoxia requiring supplemental oxygen to maintain SpO2>92% at 7 days.	7 days
Secondary	Number of adverse events.	Number of Grade 3 or 4 adverse events as determined by the DAIDS criteria over the course of 3 months from initiation of trial to measure safety and tolerability of pegylated interferon lambda. Information on adverse events will be collected during hospitalization and then as an outpatient until 90 days from the time of receipt of treatment.	until 90 days after receipt of treatment
Secondary	Days with fever	Number of days participant has a fever. Information on fever will be collected during hospitalization. Cessation of fever is defined as the beginning of the first 48 hour period without fever without the use of antipyretic drug.	during hospitalization, average of 7 days
Secondary	Time to resolution of fever	This is defined as time from initial treatment with investigational agent, to the cessation of fever, defined as the beginning of the first 48 hour period without fever without the use of antipyretic drug.	during hospitalization, average of 7 days
Secondary	Rate of progression to requiring critical care	Defined as time from initial treatment with investigational agent to deterioration of clinical condition necessitating transfer to a critical care unit and/or intubation.	during hospitalization, average of 5 days
Secondary	Overall survival	Information on survival will be collected during hospitalization and then, for those patients discharged, will be collected as an outpatient until 90 days from the time of receipt of treatment	until 90 days after receipt of treatment
Secondary	Time to discharge	This is defined as the amount of time (in days or fraction thereof) between the receipt of investigational agent and discharge from The Mount Sinai Hospital to home or nursing home, or censoring at time of death.	average of 7 days